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Abstract The understanding of key processes and signaling
mechanisms in lung development has been mainly demon-
strated through gain and loss of function studies in mice, while
human lung development remains largely unexplored due to
inaccessibility. Several recent reports have exploited the
identification of key signaling mechanisms that regulate
lineage commitment and restriction in mouse lung develop-
ment, to direct differentiation of both mouse and human plu-
ripotent stem cells towards lung epithelial cells. In this review,
we discuss the recent advances in the generation of respiratory
epithelia from pluripotent stem cells and the potential of these
engineered cells for novel scientific discoveries in lung dis-
eases and future translation into regenerative therapies.
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Introduction
Lung diseases such as cystic fibrosis (CF), chronic obstructive
pulmonary disease, and idiopathic pulmonary fibrosis are
major health issues for children and adults. Currently the
biological understanding of the etiology of many of these dis-
eases is still minimal. Therapeutic interventions are largely
based on treating symptoms, not addressing root causes. While
such therapies have improved outcomes and increased quality
of life, long-term outcomes are still poor. Presently, lung
transplantation is the treatment of choice for end-stage lung
disease. However, the shortage of donor lungs and the
increased risk of secondary complications such as graft rejec-
tion and failure [1–3] means that transplantation is a temporary
fix.
New strategies to use stem cells to regenerate or gen-
erate new lung epithelia have been of growing interest.
This review discusses some of the most recent advances in
generating lung epithelial cells from pluripotent stem cells
and how these newly engineered cells can be used to find
new therapies for lung diseases.
Embryonic Origins of the Lung
The lung is derived from the foregut endoderm. Several
patterning events cause separation from the gut tube and
other endodermal organs (e.g., liver, pancreas), ultimately
leading to the formation of the trachea and lung buds
[4, 5•]. Active reciprocal signaling between the developing
multipotent distal tip epithelium and surrounding mesen-
chyme are required for the stereotypical branching mor-
phogenesis of the lung buds, as well as early differentiation
events leading to different cell lineages. The proximal
epithelium forms first from proximal progenitors with the
emergence of neuroendocrine, basal, ciliated, and secretory
cells lining the maturing epithelium (Fig. 1). As branching
morphogenesis continues, the bronchioles eventually
branch into millions of terminal air sacs, or alveoli, where
gaseous exchange will take place after birth. Right before
birth, the respiratory epithelium is composed mainly of
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Type I alveolar epithelial cells for gas exchange and Type
II cells which secrete the surfactants required to promote
breathing at birth. Completion of lung maturation occurs
post-natally.
As the lung matures, cell turnover decreases [6] and is
very slow in the fully mature adult lung [7]. While studies
have shown some regenerative potential of the fetal and
adult lung following injury [8–12], failure of the lung to
repair itself often results in chronic inflammation, disease
progression and pathogenesis. Strategies to repair injured
lungs, by activating resident lung stem cells [13–16] or by
grafting bone marrow-derived stem cells [17–19] have
shown some success but need to be further validated. A
more direct approach based on driving differentiation of
pluripotent stem cells towards the different lung epithelial
cell types clearly holds promise. However, early efforts to
differentiate embryonic stem cells into pulmonary cells
showed limited success [20–23]. More recent studies have
taken a step-wise approach based on mimicking the stages
of normal lung development and have achieved more
promising results. Here we provide a brief overview of
these studies, and discuss the potential use of these cells for
regenerative medicine and drug discovery. For more
detailed descriptions of early endoderm and embryonic
lung development please refer to other reviews [5•, 24•,
26•, 27]
Comparative Lung Development
While the phases of lung development are similar between
mice and human, the timelines of lung development are
quite different. In the mouse, embryonic lung development
begins around embryonic day 9 and maturation of the lung
is complete about 30 days postnatally. In contrast, each
phase of fetal lung development in humans is measured in
weeks and complete maturation of the airways is not
Fig. 1 The lung at embryonic and adult stages. In the developing lung
(top panel), proximal progenitors expressing NKX2.1? SOX2? gives
rise to proximal cells lineages observed in the adult epithelium (bottom
panel). The distal tip progenitors marked by NKX2.1? FOXP2? or
NKX2.1? SOX9? contribute to stereotypical branching morphogen-
esis and eventually the respiratory epithelial cells
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achieved until up to 2 years post-natally [26•]. In addition,
there are clear differences in anatomical and regional dis-
tribution of the cell types from the large airways through to
the intralobar airway epithelium between mouse and
human [12, 28–33]. The current knowledge of lung
development is largely based on gain- and loss-of-function
studies in mice [5•, 25, 26•, 27, 34, 35]. This knowledge
has been the basis of attempts at directed differentiation of
stem cells to lung epithelium. Comparative studies of lung
differentiation from mouse and human pluripotent cells
have suggested that the general rules of differentiation are
similar. However, the fine details may differ in ways that
could have significance for the sought-for regenerative
outcomes. Careful study of the development of different
lung cell types from stem cells of mouse and human origin
may help reveal the underlying similarities and differences
in terms of timing, marker expression and potentially even
differentiation pathways.
Directed Differentiation of Pluripotent Stem Cells
to Lung Epithelial Cells
The first indication of the developing embryonic lung
endoderm is the expression of the transcription factor
Nkx2.1 (or TTF1), in the anterior foregut compartment.
The first hurdle, therefore, in generating lung epithelial
cells from pluripotent stem cells is to establish an Nkx2.1-
expressing embryonic lung endoderm from definitive
endoderm (Fig. 2). The first study to show directed dif-
ferentiation of human embryonic stem cells into anterior
foregut endoderm progenitors was published by Green
et al. [36••] in early 2011. Using a well established method
to generate definitive endoderm [37] with high concentra-
tion of Activin A, Green et al. [36••] demonstrated that
inhibition of both the BMP and TGF-b signaling pathway
using NOGGIN (a physiological inhibitor) and SB431452
(a pharmacological inhibitor), respectively, can induce
differentiation of definitive endoderm cells into anterior
foregut endoderm (AFE). Up-regulated expression of the
foregut marker SOX2 and a concomitant down-regulation
of the hindgut marker CDX2 were observed. Dorsoventral
patterning of the anterior foregut gives rise to the dorsal
esophagus and the ventral lungs and trachea. To specify the
lung from the AFE cells, the authors used a combination of
Wnt3a, FGF10, KGF, BMP4 and EGF to generate up to
37 % NKX2.1? lung cells. Addition of retinoic acid
induced expression of the classical Type II alveolar cell
marker surfactant protein-C (SFTPC) and the ciliated cell
marker FOXJ1. This was the first study to present a method
to enrich for AFE cells, which can then be directed to
differentiate into more mature AFE-derived lineages.
Using embryonic stem cells derived from a mouse line
carrying an Nkx2.1–GFP reporter, Longmire et al. [38••]
adopted the step-wise protocol from Green et al. [36••] to
generate ventral foregut endoderm with the exception that
they also included a high concentration of FGF2. Inter-
estingly, exposure of definitive endoderm cells to NOG-
GIN and SB431452 alone was sufficient to induce GFP
expression in up to 21 % of the cells. Gene expression
profiling of the sorted GFP? cells after treatment with
Wnt3a, FGF10, KGF, BMP4, EGF and FGF2 revealed up-
regulated expression of both lung and thyroid lineage
genes. Further differentiation of the cells with FGF2,
FGF10, and a mixture of KGF, dexamethasone, cAMP and
IBMX (also known as DCI and previously shown to induce
transcriptomic changes in fetal lung epithelial cells [39,
40]), resulted in down-regulation of Nkx2.1 in approxi-
mately half of the cells. Of the Nkx2.1-negative population,
up to 40 % expressed a marker associated with Type I
alveolar cells (Pdpn or T1a). Of the Nkx2.1-positive cells,
some cells expressed the pro-form of SFTPC, suggestive of
Type II cells. Recellularization of decellularized mouse
lungs with Nkx2.1–GFP? cells showed some engraftment
of these donor cells as Type I T1a-expressing cells in the
parenchyma.
Mou et al. [41••] used a slightly different approach to
generate multipotent lung and airway progenitors from
mouse and human pluripotent stem cells. Starting with a
monolayer method of differentiation, Mou et al. [42].
adapted a previously published method of generating
definitive endoderm with high efficiency. Unlike the
studies by Green et al., and Longmire et al., TGFb inhi-
bition with SB431452 alone was sufficient to induce
anterior patterning of the definitive endoderm cells. Fol-
lowing the addition of BMP4, FGF2 and a GSK3 inhibitor,
up to 10 and 30 % of Nkx2.1 expressing cells were
observed with mouse cells and human induced pluripotent
stem (iPS) cells, respectively. To generate airway progen-
itors from the Nkx2.1-expressing cells, a combination of
retinoic acid, BMP7, KGF, Wnt antagonism and MAPK/
ERK inhibition was used. This produced up to 18 %
Nkx2.1? Sox2? proximal progenitors in the population of
cells. Of the total Nkx2.1? population, a smaller percent-
age (1–4 %) also expressed p63, a marker associated with
conducting airway basal cells [29]. Interestingly, using an
in vivo model of differentiation with a mixed population of
lung endoderm cells in matrigel and injected subcutane-
ously in immunodeficient mice, epithelial spheres were
observed that contained Clara cell, ciliated cell, goblet
cell and basal cell lineages. The efficiency of differentia-
tion both in vivo and in vitro appears low and while
proximal cell lineages were established, distal lung
parenchymal epithelia characterized by Type I and Type II
cells were not generated even though Nkx2.1? Sox9? or
Nkx2.1? FoxP2? multipotent distal progenitor cells were
established.
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Two recent publications have bypassed the early step-
wise differentiation process and showed some success in
generating distal respiratory epithelial cell types.
Schmeckebier et al. [43] recently reported that KGF, a
known epithelial mitogen [44] that can promote maturation
of Type II fetal rat alveolar cells [45], can induce differ-
entiation and maturation of mouse ES and iPS-derived
Type II cells in combination with glucocorticoids, cAMP-
derivatives and compounds that elevate cAMP levels.
While Longmire et al., used DCI and KGF to induce
alveolar differentiation from lung endoderm progenitors,
Schmeckebier et al., added KGF early in the differentiation
process from embryoid bodies, followed by addition of
DCI and KGF at day 14. They report a 14-fold greater
expression of SP-C and fivefold greater expression of
aquaporin-5 (Type I alveolar cell marker) compared to
unstimulated controls within 10 days. Electron microscopy
revealed features of Type II alveolar cell structures such as
apical microvilli and electron-dense lamellar bodies.
Another study by Siti-Ismail et al. [46] reported an
impressive ability to generate Type II cells that does not
rely on addition of defined exogenous growth factors, but
rather on a bioengineering process utilizing encapsulation
of mES cells in hydrogels and culture in conditioned media
from an alveolar cancer cell line (A549) in a rotary bio-
reactor [47]. In as little as 5 days, up to 50 % of the cells
were reported to be Type II alveolar cells that under
electron microscopy exhibited ultrastructural features such
as microvilli and lamellar bodies. Furthermore, these cells
could be maintained in the bioreactor for 100 days and
plated onto 2D cultures without differentiating into Type I
cells. It would be interesting to know how well these
engineered Type II cells integrate and function in vivo in
respiratory epithelia and whether human pluripotent stem
Fig. 2 Differentiation strategies to generate pulmonary epithelial cell
lineages from pluripotent stem cells. Arrows demarcate the lineages
achieved from each step. The supplements used for the generation of
a particular cell lineage is demarcated by the same color-code. A new
color-code for the supplements used means the differentiation step
drives the generation of a separate reported cell population but the
preceding pathway(s) are the same as indicated
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cells can also be differentiated as efficiently using this
method.
Rather than focus on distal alveolar epithelium, we
recently outlined an in vitro differentiation protocol for
generating proximal airway epithelia from human pluripo-
tent stem cells, the cell population that is most affected in CF
patients. The cystic fibrosis transmembrane conductance
regulator (CFTR) protein channel [48••] is involved in
chloride and water transport across the airway epithelium.
Mutations in this gene lead to failure to maintain proper
mucociliary transport and clearance of pathogens. In our
step-wise differentiation process, pluripotent stem cells were
induced to differentiate progressively into definitive endo-
derm, anterior foregut endoderm, proximal epithelial pro-
genitors, followed by proliferation, maturation and
polarization of the proximal epithelia in an air–liquid inter-
face. The result was maturation of patches of tight junction-
coupled differentiated airway epithelial cells. These cells
showed up-regulated expression of several characteristic
proximal large airway markers, including the polarized
apical localization of the CFTR protein needed for proper
chloride transport. The CFTR transport functions were
active in the differentiated cells as demonstrated by
responsiveness to cAMP agonists and a CFTR potentiator in
a modified iodide efflux assay for CFTR activity. This study
also showed generation of mature airway epithelia from
human iPS cells, derived from CF patients. Analysis of these
cells shows great promise to study the role of unique genetic
modifiers in CFTR activity [49–51] especially since treat-
ment of the CF-iPS-derived airway epithelial cells with a
small molecule compound, C18, resulted in partial correc-
tion of the CFTR protein in the plasma membrane, sug-
gesting that these cells could be used to model CF in vitro.
It should be noted, however, that this protocol, while suc-
cessful in generating around 40–50 % CFTR? polarized lung
epithelial cells, still results in a heterogeneous mixture of other
endoderm cell types. To date, there has not been a lung dif-
ferentiation protocol reported that produces a homogeneous
cell type of interest. Future refinements, including sorting
appropriate cells at appropriate stages of the differentiation
protocol, will be needed to solve the heterogeneity issue. Fur-
thermore, while functional activity of CFTR showed levels
similar to control epithelial cell lines, future studies will also
need to determine the similarities between CFTR function from
iPS-derived cells compared to normal post-natal bronchial
primary epithelial cells.
Application of Engineered Lung Cells
Disease Modeling
Recent advances in generating airway and distal lung epi-
thelial cells and the ability to generate a renewable source
of these cells in vitro offers great hope in using these cells
to study lung diseases. Reprogramming of somatic cells
into induced pluripotent stem (iPS) cells has created a
powerful and unlimited source of patient-specific cells
bearing many pulmonary congenital defects [41••, 48••,
52]. These cells carry the mutation that causes or is asso-
ciated with the disease and can be used to model the dis-
ease in vitro. The ability to generate tissue-specific cells
from iPS cells offers great opportunities to model many
lung diseases in vitro, including the pathogenesis of lung
diseases caused by respiratory infections and other con-
genital defects such as surfactant protein deficiency [53].
For the latter, the lack of reliable methods to generate Type
II alveolar cells from human iPS cells remains an imped-
iment to progress towards an in vitro model of this lung
disease. A promising example of an application of iPS for
disease modeling is CF, which is the most common life
shortening congenital disease amongst Caucasians. The
disease affects epithelial tissues lining multiple organs
throughout the body, including the airways, skin, intestines,
pancreatic ducts, and reproductive organs. Lack of ion
transport across the airway epithelium leads to improper
airway fluid balance, mucous thickening and defective
mucociliary clearance, thereby creating a niche for chronic
bacterial infections in the airways. These infections are the
main cause of mortality in CF patients. Modeling CF has
been difficult. The traditional CF knockout mouse model
does not recapitulate the pulmonary aspect of the disease,
and the availability of patient-specific CF lung epithelium
is limiting for in vitro studies. Other animal models of CF,
such as swine [54] and ferret [55], display airway pheno-
types similar to humans and are useful surrogates for some
human studies. However, they cannot model the genetic
heterogeneity in disease outcome shown in humans.
Patients carrying the same CF mutation will have varying
degrees of disease progression and responses to therapy.
This is in part due to genetic modifiers that have been
shown to affect disease progression [49, 56, 57]. Genera-
tion of CF patient iPS cell-derived airway cells in vitro is
thus a critical tool for studying the molecular pathways, the
effects of environmental insults and the genetic modifiers
of CF pathogenesis.
Drug Screening
Patient-derived induced iPS cells hold great promise for
patient-specific drug discovery. The most common CF
mutation (*70 % of cases) in the CF gene is caused by a
trinucleotide in-frame deletion at position 508 (F508del) of
the peptide sequence [58]. Consequently the mutant CFTR
protein does not fold properly in the endoplasmic reticulum
and is rapidly targeted for degradation instead of translo-
cating to the cell membrane for chloride transport. Recent
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studies have shown that small molecules called ‘‘corrector’’
compounds are effective in rescuing some of the mutant
defects in protein processing and trafficking [59–61]. As a
proof-of-concept, we recently reported that CF-iPSC-
derived lung epithelial cells could be used to validate novel
CF corrector compounds. An active analog of the small
molecule VX-809 (vertex 809 currently in phase II clinical
trials) promoted plasma membrane accumulation of the
mature complex glycosylated form of CFTR protein (band
C) in F508del CF-iPS cell-derived lung epithelial cells
[48••]. The CF patient iPS cell-derived airway epithelial
cells therefore provide a novel platform for cell-based
patient-specific screens to find new treatments for CF and
other airway diseases [49, 56, 57]
Small molecule screening could also be used to identify
novel compounds that improve the directed differentiation
of iPS cells to lung epithelial cells. Current differentiation
methods use recombinant proteins from xenobiotic sources
(bacteria or insect cells) and have high batch to batch
variability. In addition, the cost of these recombinant pro-
teins can be astronomical if scale-up of the differentiation
process was needed for regenerative purposes. Small
molecules, therefore, can be used to improve and control
the cell differentiation process. Use of less economical, but
highly efficient and reproducible compounds, has been
previously shown by Borowiak et al. [62] in driving
definitive endoderm in mouse and human ESC and by
Chen et al. [63] in driving human ESC into pancreatic
progenitors. Small molecules can theoretically be used to
generate specific lung progenitor populations or direct
certain lung lineages over others.
Overall, the ability to generate a renewable source of
airway epithelial cells from pluripotent stem cells holds
great promise for high-content screens for therapy.
Lung Regeneration
Cell replacement strategies have shown some success in
several models of lung injury [64–66]. Regeneration by
extrapulmonary sources such as the bone marrow [18, 67–
69] and cord blood [70, 71] have identified these cells as
potential sources of stem cells for therapeutic strategies.
Bioengineering of lung organoids using simple biode-
gradable scaffolds seeded with fetal lung cells [72–74] is
also a promising new avenue for tissue replacement
approaches. However, use of these scaffolds to differentiate
and support non-lung-derived cells such as pluripotent stem
cells has yet to be determined. One of the limitations in
these organoid cultures is the importance of mechanical
stretch in activating pathways involved in epithelial dif-
ferentiation and proliferation [75–77].
Recent advances in the decellularization of the lung may
provide a more plausible system since most of the lung
extracellular matrices are preserved and allow initial binding of
the donor cells to the lung tissue [78–81]. In 2010, two seminal
papers by Ott et al. [82] and Petersen et al. [83] demonstrated
that cadaveric rat lungs could be safely decellularized leaving
most of the extracellular matrix intact and then using a biore-
actor, recellularized with epithelial and endothelial cells. Pet-
ersen et al. [83] showed that the engineered lungs had regional-
specific reorganization of the cells mechanical properties
similar to native lung tissue. Furthermore, both papers dem-
onstrated that when these engineered lungs were orthotopically
transplanted short-term into a recipient rat, the lungs partici-
pated in gas exchange. These two publications has since
spurred many publications demonstrating reconstitution of the
decellularized lung with a variety of cell types, including
mesenchymal stem cells [79, 80] and fetal lung cells [78]. The
use of pluripotent stem cell-derived cells in recellularizing the
lungs is promising since these cells offer an unlimited supply of
autologous cells for repopulation.
In the excitement around the decellularized lung model,
it is worth remembering that the adult lung is comprised of
at least 40 different cell types with specialized functions
including gas exchange, metabolism of xenobiotics, and
immunity to name a few. Therefore, to completely reca-
pitulate the cell lineages and functions of the lung in a
decellularized model and then use these lungs as replace-
ment organs in transplantation remains a distant horizon.
However, as more studies identify methods to generate
various mature lung cell types or early lung progenitor cells
that can potentially differentiate into several cell lineages
in vivo (Fig. 2), perhaps partial regeneration of the lung
can be accomplished.
The recent success of a main stem bronchus replacement
in 2008 with a decellularized human donor trachea re-
cellularized with the recipient’s own respiratory epithelial
and stem cell-derived chondrocytes [84] has caused much
excitement in engineering bioartificial airways as replace-
ment strategies for lung diseases. The same group recently
demonstrated the clinical success of transplanting a ‘‘bio-
artificial nanocomposite’’ seeded with the patient’s bone
marrow mononuclear cells that partly regenerated the tra-
cheobronchial airway with healthy epithelium after
5 months [85]. Long-term follow-up is yet unknown in
these patients and the mechanism of how these cells
regenerate remains unclear. A fuller understanding of this
process might provide clues as to how to promote endog-
enous repopulation of other more complex organs, based
around decellularized or artificial matrices.
Potential of Direct Conversion of Fibroblasts
to Epithelial Cells
There is some evidence for direct conversion of fibroblasts
into neurons [86], cardiomyocytes [87] and hematopoietic
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cells [88], based on the introduction of the four repro-
gramming transcription factors (OCT4, CMYC, SOX2,
KLF4) combined with microenvironmental cues to direct
lineage commitment. It is believed that the reprogramming
regimen resets the epigenetic fate map of the cells ren-
dering the cells in an epigenetically unstable state. This
then allows the influence of extracellular cues such as cell
culture conditions to select for or direct phenotypic chan-
ges of these cells in their new microenvironment. It has yet
to be shown that this direct conversion or ‘‘transdifferen-
tiation’’ of cells can be done using conditions that would
support airway or lung epithelial cell growth. This avenue
of research is certainly worth exploring as it could avoid
the long and complex process of maturing lung cell types
from embryonic precursors.
Conclusion
Current methods of generating lung epithelial cells from
pluripotent stem cells are not 100 % efficient and cultures
are often contaminated with other endodermal cell types,
making it difficult to use these cells for reliable high-con-
tent drug screens and tissue regeneration. Future efforts
will need to identify methods to isolate embryonic lung
progenitor cells from the differentiating cultures or identify
methods to generate postnatal stem cells that can differ-
entiate into all lung cell types in vitro. In addition, in vivo
assessment of the potential to functionally integrate with
native cells and generate mature lung epithelial cell lin-
eages should become the gold standard for validating any
lung cell populations generated in vitro.
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